Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Celltrion and Sanofi-Aventis In Line With 2008 Strategic Alliance For Monoclonal Antibodies

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Despite Celltrion's claims that it is shifting away from its contract manufacturing business to focus on biosimilars, the company revealed an ongoing deal with Sanofi-Aventis for clinical materials and process development for monoclonal antibody therapeutics and announced the near completion of its CMO plant

You may also be interested in...



Optimism Building For Korea's Celltrion Amid Expectations For Biosimilars

SEOUL - Optimism is building for South Korea's biopharmaceutical firm Celltrion and its biosimilar program, as seen in the recent surge of its stock price

Optimism Building For Korea's Celltrion Amid Expectations For Biosimilars

SEOUL - Optimism is building for South Korea's biopharmaceutical firm Celltrion and its biosimilar program, as seen in the recent surge of its stock price

Korea's Celltrion Completes Phase I Clinical Trials For Biosimilars Based On Roche And Johnson & Johnson Products

SEOUL - South Korean biotech firm Celltrion said it has successfully completed Phase I clinical trials on its biosimilar versions of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade(infliximab)

Related Content

UsernamePublicRestriction

Register

SC073314

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel